How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,961 results for

Ketoconazole

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

188. Precocious puberty

: gonadotrophin-dependent (GDPP; due to premature activation of the hypothalamo-pituitary-gonadal axis) and gonadotrophin-independent (GIPP; due to autonomous secretion of sex steroids). History should be directed dependent on whether puberty is consonant or disconsonant (i.e., whether the pattern of endocrine change is the same as in normal puberty or not). Treatment of GDPP is usually straightforward with gonadotrophin-releasing hormone agonists. GIPP is more difficult to treat; may require ketoconazole

2018 BMJ Best Practice

189. Achlorhydria

present with signs and/or symptoms of iron, cobalamin (vitamin B12), or calcium deficiency and may predispose to enteric infection with organisms such as Clostridium difficile , Salmonella , and Campylobacter . May interfere with the absorption of certain drugs including thyroxine, ketoconazole, itraconazole, and dipyridamole. The most common cause of hypergastrinaemia. Although the prognosis is excellent, it carries a small increased risk for the development of gastric adenocarcinoma and gastric

2018 BMJ Best Practice

190. Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19

to Commission A17-19 29 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - 5 - Table 3: Characteristics of the intervention – RCT, direct comparison: alectinib vs. chemotherapy (pemetrexed or docetaxel) (continued) Study Intervention Comparison Non-permitted concomitant treatment ? strong CYP3A inducers (e.g. rifampicin, rifabutin, phenobarbital, phenytoin, carbamazepine and St. John’s Wort, grapefruit or grapefruit juice) or inhibitors (e.g. ketoconazole) within 2 weeks or 5 half (...) (e.g. ketoconazole, itraconazole, clarithromycin, atazanavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole, as well as grapefruit and grapefruit juice) and CYP3A4 inducers ? non-permitted concomitant treatment according to the SPC ALK: anaplastic lymphoma kinase; BCRP: breast cancer resistance protein; BID: twice daily; CYP3A: cytochrome P450 3A; IM: intramuscular; IV: intravenous; NSCLC: non-small cell lung cancer; P-gp: P-glycoprotein; RCT: randomized controlled

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

191. Atezolizumab (non-small cell lung cancer) ? Benefit assessment according to §35a Social Code Book V

ibuprofen), diphenhydramine and/or cimetidine, or other H2 receptor antagonists ? after cycle 1, day 14 radiotherapy for alleviation of pain Docetaxel arm: ? granulocyte-stimulating medications ? antiemetics, antiallergics if approved by the investigator Atezolizumab arm: ? = cycle 2 systemic corticosteroids, TNFa inhibitors; epinephrine, antihistamines for the treatment of AEs Non-permitted concomitant treatment: Docetaxel: ? CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin (...) , day 14 radiotherapy for alleviation of pain ? bisphosphonates for prevention of skeletal-related events Docetaxel: ? granulocyte-stimulating medications ? antiemetics, antiallergics if approved by the investigator Atezolizumab: ? = cycle 2 systemic corticosteroids, TNFa inhibitors; epinephrine, antihistamines for the treatment of AEs Non-permitted concomitant treatment: Docetaxel: ? CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

192. Guanfacine (Intuniv) for attention deficit hyperactivity disorder Full Text available with Trip Pro

to 24 hours for the development of more serious toxicity (including coma, bradycardia, and hypotension) due to the possibility of delayed onset of these symptoms. For information about reporting adverse reactions to the TGA, or to report suspected adverse reactions online, see the . Drug interactions Guanfacine is a substrate of CYP3A4/3A5 and caution is required if it is co-administered with CYP3A4/3A5 inducers (such as rifampicin) and inhibitors (such as ketoconazole). Co-administration

2019 National Prescribing Service Limited (Australia)

193. Kaiser Permanente National Cholesterol and Cardiovascular Risk Clinician Guide

mg Avoid lovastatin > 20 mg Dronedarone Use atorvastatin up to 40 mg Avoid simvastatin > 10 mg Avoid lovastatin > 20 mg Gemfibrozil Stop gemfibrozil in those on statins or needing statins. For TG = 500 mg/dL, add EPA/DHA 2-4 g/day and retest. If TG remain elevated, see TG algorithm (Fig 2) Itraconazole, ketoconazole, or posaconazole, Use atorvastatin up to 20 mg or rosuvastatin any dose Avoid simvastatin and lovastatin. For short-term course, statin should be interrupted Nefazodone Use

2018 Kaiser Permanente National Guideline Program

194. Fluconazole

were studied at the Gynecological Clinic of Peking University Shenzhen Hospital from January 1, 2009 through December 31, 2010. Patients with SVVC were treated with two doses of miconazole 2015 11. Comparative clinical trial: fluconazole alone or associated with topical ketoconazole in the treatment of pityriasis versicolor. 27532525 2016 08 18 2017 01 10 2017 01 11 0041-4131 94 2 2016 Feb La Tunisie medicale Tunis Med Comparative clinical trial: fluconazole alone or associated with topical (...) ketoconazole in the treatment of pityriasis versicolor. 107-11 The efficacy of ketoconazole and fluconazole in pityriasis versicolor had been proved. To compare the efficacy and the safety of two doses (...) of fluconazole given 1 week apart alone or associated to ketoconazole shampoo. Our study included all patients with pityriasis versicolor who attended in dermatology department of Habib Thameur Hospital, Tunis (over a 21-month period). During the considered period, patients were randomly assigned

2018 Trip Latest and Greatest

195. Nystatin

-41 984105 Curr Med Res Opin. 1975;3(2):83-8 1095310 Br J Obstet Gynaecol. 1975 Nov;82(11):922-6 1191608 MMW Munch Med 1981 11. A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin , and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin , and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis - Full Text View - ClinicalTrials.gov A service of the U.S. National Institutes of Health Example: "Heart attack" AND "Los Angeles (...) " Search for studies: Study Record Detail A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin , and Ketoconazole Tabs (...) . In adults, ketoconazole is used and sometimes oral nystatin . Both drugs are relatively expensive compared to GV solution and ketoconazole has significant side effects especially in association with some of the treatments for HIV related problems. In children, either GV solutions or nystatin are used, GV is a fraction of the cost of nystatin . GV at 1% solution discolours

2018 Trip Latest and Greatest

197. Sufentanil citrate (Dzuveo) - Pain

on the clinical studies conducted for Zalviso (SST 15 µg): the BA study IAP102, the two PK studies IAP101 and ARX-F01-01 and the PK drug interactions study (ketoconazole) IAP104. The results of the BA and PK studies submitted to support the marketing authorisation for SST 30 mcg showed that systemic exposure of sufentanil after Sufenta IV 30 mcg was greater than after single- dose SST 30 mcg. The mean bioavailability (F) approximately the same after administration of single- dose SST 30 mcg and 2 doses of SST

2018 European Medicines Agency - EPARs

198. Budesonide (Jorveza) - to treat adults with eosinophilic oesophagitis

is not a substrate for OATP1B3. Assessment report EMA/774645/2017 Page 23/83 Conversely in vitro interaction studies (Lu et al.: Drug Metab Dispos 2008 and Jönsson et al.: Drug Metab Dispos. 1995) have demonstrated strong inhibition of the metabolic degradation of budesonide by specific inhibitors of CYP3A4; i.e. ketoconazole. Contrary to CYP3A4 inhibitors, compounds or drugs such as carbamazepine and rifampicin, which are able to induce CYP3A4, might reduce the systemic exposure but probably also the local (...) 850.1500) by end of 2018, to which the applicant committed. 2.3.6. Discussion on non-clinical aspects The literature review on the safety pharmacology of budesonide is considered adequate. In vitro studies have demonstrated strong inhibition of the metabolic degradation of budesonide by specific inhibitors of CYP3A4; i.e. ketoconazole. In humans a clear influence of ketoconazole on the pharmacokinetics of budesonide was observed. The Applicant pointed out that a potential inhibition of the metabolic

2018 European Medicines Agency - EPARs

199. Drug-induced gynaecomastia

; some cancer drugs; ketoconazole; and isoniazid. When a patient complains of gynaecomastia, it is worthwhile reviewing with him the list of drugs he is taking or has recently taken, not forgetting products which are not classified as medicines. Their role should be considered among the range of potential causes. ©Prescrire 1 November 2018 Share Share Download the full review. | | | Prescrire Your change of address has been received and will be processed promptly but will not appear instantaneously

2018 Prescrire

200. Dolutegravir sodium rilpivirine hydrochloride (Juluca) - HIV Infections

First-order rate of absorption KF Karl Fischer titration KTZ Ketoconazole LC-MS-MS Liquid chromatography tandem mass spectroscopy LDL Low-density lipoprotein LDPE Low density polyethylene LOCF Last observation carried forward LOD Loss on drying LPV/RTV Lopinavir/ritonavir LS Least square MAH Marketing authorisation holder MATE Multidrug and toxin extrusion transporter N(t)RTI Nucleotide HIV-1 reverse transcriptase inhibitor NA Not applicable NDA New Drug Application NF National formulary NGMN

2018 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>